Daiichi Sankyo, Inc. (4568.t) Release: New Guidelines From the American Association of Clinical Endocrinologists (AACE) Identify Welchol® (colesevelam HCI) for Lowering Both A1C and LDL-Cholesterol in Patients With Type 2 Diabetes
6/7/2013 9:12:48 AM
More...
|
Perosphere Inc. and Daiichi Sankyo, Inc. (4568.t) Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban
4/25/2013 10:49:34 AM
More...
|
Daiichi Sankyo, Inc. (4568.t) Release: Global Pharmaceutical Leader Chooses Acsis Enterprise Serialization Management Suite to Achieve e-Pedigree Compliance
4/10/2013 9:33:31 AM
More...
|
ArQule, Inc. (ARQL) Regains Rights to AKT Inhibitor From Daiichi Sankyo, Inc. (4568.t)
4/1/2013 7:05:04 AM
More...
|
Daiichi Sankyo, Inc. (4568.t) Will Lay Off Up to 300 Positions
3/4/2013 7:54:54 AM
More...
|
Daiichi Sankyo, Inc. (4568.t) Reps Charge Sex Discrimination
2/12/2013 7:22:58 AM
More...
|
Daiichi Sankyo, Inc. (4568.t) and ArQule, Inc. (ARQL) Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial for Tivantinib
1/31/2013 10:19:49 AM
More...
|
ArQule, Inc. (ARQL), Daiichi Sankyo, Inc. (4568.t)'s Colorectal Cancer Drug Fails Trial
1/11/2013 7:20:56 AM
More...
|
Daiichi Sankyo, Inc. (4568.t) CEO John Gargiulo Elected as National Pharmaceutical Council's Chairman of the Board
11/5/2012 10:05:14 AM
More...
|
Daiichi Sankyo, Inc. (4568.t) Completes Enrollment in Hokusai - VTE, Investigating Once-Daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
10/25/2012 10:46:22 AM
More...
|
|